探索GLP-1R激动剂与甲状腺和副甲状腺相关疾病之间的因果关系:一项门德尔随机化研究
Caihong Li1, Keyu Shen2, Lingfeng Pan3
1University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nürnberg, Hartmannstr. 14, 91054 Erlangen, Germany.
Journal of diabetes and metabolic disorders
|February 10, 2025
概括
类似葡萄糖-1受体 (GLP-1R) 激动剂可能会增加甲状腺功能障碍症的风险. 这项研究没有发现甲状腺功能障碍与甲状腺功能障碍的因果关系,建议对使用这些糖尿病和肥胖药物的患者进行副甲状腺监测.
科学领域:
- 内分泌学 在内分泌学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 葡萄糖类-1受体 (GLP-1R) 激动剂广泛用于2型糖尿病和肥胖管理.
- 人们担心GLP-1R激动剂与甲状腺癌风险增加之间存在潜在的关联.
研究的目的:
- 研究甲状腺和副甲状腺组织中的GLP-1R基因表达及其各自的功能之间的因果关系.
- 用遗传数据评估GLP-1R激素对甲状腺和副甲状腺健康的影响.
主要方法:
- 进行了基于总结数据的门德尔随机化 (SMR) 分析.
- 使用了来自GTEx V.8和英国生物库的遗传数据.
- 该研究的重点是甲状腺和副甲状腺组织中的基因表达.
主要成果:
- 增加GLP-1R基因表达被确定为甲状腺功能障碍症的危险因素.
- 在GLP-1R基因表达和甲状腺功能障碍之间没有建立起因果关系.
- 该研究发现没有证据表明GLP-1R激动剂与甲状腺癌风险有关.
结论:
- 常规评估副甲状腺功能和激素水平,建议在患者处方GLP-1R激动剂.
- 虽然GLP-1R激动剂对代谢条件有益,但它们对甲状腺侧状腺健康的影响值得注意.
- 进一步的研究可能会澄清观察到的与甲状腺功能障碍症相关的确切机制.
相关概念视频
Hormonal Regulation
43.1K
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
43.1K
Hormones and Bone Tissue
2.6K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
2.6K
Synthesis and Regulation of Thyroid Hormones
4.1K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.1K
The Parathyroid Glands
1.8K
The two pairs of parathyroid glands embedded within the posterior surface of the thyroid gland are restricted by a dense capsule around them. These glands comprise two distinct cell populations—parathyroid oxyphil and parathyroid principal cells- pivotal in calcium homeostasis.
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
1.8K
Oral Hypoglycemic Agents: Biguanides and Glitazones
160
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
160
Glucagon-like Receptor Agonists
291
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
291


